ISRCTN70449927进行中（未招募）4 期
A randomized, double-blind, placebo-controlled investigation to evaluate the performance and safety of SPL7013 Nasal Spray in non-hospitalised patients with COVID-19
Starpharma (Australia)0 个研究点目标入组 231 人开始时间: 2022年12月1日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 231
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Females and males aged 16 years and older
- •2. Positive PCR test for COVID-19 within 2 days (if possible 24 hours) of enrolment
- •3. Score of 1 to 3 on the WHO Clinical Progression Scale (CPS)
- •4. Able to understand and willing to comply with the investigation plan procedures and restrictions
排除标准
- •1. Allergy to any ingredient in the device formulation (SPL7013, parabens, Carbopol 974P, glycerine, propylene glycol, or EDTA)
- •2. Treated or about to be treated with medications administered by inhalation (with exception of asthma-related treatment) or via the nasal route
- •3. Pregnant, planning to become pregnant, or breastfeeding, or within 3 months of last pregnancy outcome
- •4. In the opinion of the investigator, should not participate in the investigation
研究者
相似试验
已完成
1 期
A randomized, double-blind, placebo-controlled investigation of the safety, tolerability and pharmacokinetics of 1% SPL7013 nasal spray in healthy volunteers when administered four times a day for 14 daysCOVID-19Infection - Other infectious diseasesRespiratory - Other respiratory disorders / diseasesACTRN12620001371987Starpharma Pty Ltd40
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-BEBarrier Therapeutics nv48
已完成
2 期
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic urticaria10002426NL-OMON30213Barrier Therapeutics16
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-CZBarrier Therapeutics nv48
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-NLBarrier Therapeutics nv48